InfoMedix is Australia's leading digitised medical records solution. Founded in 2000, InfoMedix is now installed in over 30 hospitals around Australia. The key product is a digital medical record solution that consolidates patient centric information to become the complete medical record. Key to this technology is an innovative scanning solution which allows hospitals to digitise the traditional paper based medical record.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ACROBIOSYSTEMS ANEURO PARTNERS WITH DIAGNOSTIC BIOCHIPS TO ACCELERATE NEUROSCIENCE DRUG DISCOVERY

PRNewswire | June 19, 2023

news image

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization. Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field potential an...

Read More

Business Insights

HALOZYME COMPLETES ANTARES PHARMA ACQUISITION

Halozyme Therapeutics, Inc. | May 30, 2022

news image

Halozyme Therapeutics, Inc. announced the successful completion of its acquisition of Antares Pharma, Inc. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not vali...

Read More

JAZZ PHARMACEUTICALS ANNOUNCES NEW RESEARCH COLLABORATION WITH REDX PHARMA TO DISCOVER AND DEVELOP TWO TARGETED CANCER THERAPIES

Jazz Pharmaceuticals | September 09, 2020

news image

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agre...

Read More

MOBERG PHARMA DECIDES ON FULLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 150 MILLION

Moberg Pharma | November 06, 2020

news image

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...

Read More
news image

Pharma Tech

ACROBIOSYSTEMS ANEURO PARTNERS WITH DIAGNOSTIC BIOCHIPS TO ACCELERATE NEUROSCIENCE DRUG DISCOVERY

PRNewswire | June 19, 2023

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization. Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field potential an...

Read More
news image

Business Insights

HALOZYME COMPLETES ANTARES PHARMA ACQUISITION

Halozyme Therapeutics, Inc. | May 30, 2022

Halozyme Therapeutics, Inc. announced the successful completion of its acquisition of Antares Pharma, Inc. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not vali...

Read More
news image

JAZZ PHARMACEUTICALS ANNOUNCES NEW RESEARCH COLLABORATION WITH REDX PHARMA TO DISCOVER AND DEVELOP TWO TARGETED CANCER THERAPIES

Jazz Pharmaceuticals | September 09, 2020

Jazz Pharmaceuticals plc today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. Under the terms of the research collaboration agre...

Read More
news image

MOBERG PHARMA DECIDES ON FULLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 150 MILLION

Moberg Pharma | November 06, 2020

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us